Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Pfizer, Inc. (PFE) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 10, 2014.
Market data for PFE model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are
accounted for in this model in the form of the historical data coincided with outbreaks and other
global events in the past used to train ML prediction model for PFE.
Model is being retrained on a daily basis.
| Float | 5608M |
| P/E | 10.27 |
| Shares Outstanding | 5611M |
| % Held by Insiders | 0.05% |
| % Held by Institutions | 66.50% |
| EPS (last reported FY) | $4.42 |
| EPS (last reported Q) | $1.62 |
| EPS, estimated (last reported Q) | $1.66 |
| Total revenues | $81 B |
| Net income | $22 B |